International Journal of Clinical Oncology

, Volume 3, Issue 2, pp 108–112 | Cite as

Establishment and characterization of a novel cancer cell line (SMOV-1), derived from the ascitic fluid of a woman with ovarian cancer who had never responded to chemotherapeutic drugs

  • Tomohiro Iida
  • Kyoko Yonamine
  • Hisakiyo Takeuchi
  • Kazuhiko Hayashi
  • Takashi Meguro
  • Toshihito Shinagawa
  • Akira Amemiya
Original Article



A novel cell line, designated SMOV-1, was established from the ascitic fluid of a woman with ovarian cancer. This report describes the process of establishment and characterization of this cell line.


The case involved a woman who had undergone a surgical intervention, due to a serous papillary adenocarcinoma of the ovary. She received the combination chemotherapy of PAC (cisplatin +doxorubicin+cyclophosphamide) 6 times after the surgery. However, as a result of malignant pleural effusion during chemotherapy, she died 7 months after surgery. Before surgery, ascitic fluid was removed from the patient for cell culture, after obtaining her consent. The cells were successfully subcultured, and designated SMOV-1.


The cell line gave a pavement-stone pattern, without contact inhibition. SMOV-1 could also be transplanted into nude mice, and the tissue showed reconstruction of the original tumor. The chromosome number of the SMOV-1 cells was 57, and the DNA index was 2.28. The population-doubling time of the SMOV-1 cells was 61.4 hours. Cultured SMOV-1 cells were still capable of producing the tumor-associated antigens CA 125, CA 19-9, and sTn (sialosyl-Tn).


We propose that this novel cell line is of possible use for the investigation of drug resistance in ovarian cancer.

Key words

ovarian cancer in vitro tumor marker drug resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cramer DW. Lactase persistence and milk consumption as determinants of ovarian cancer risk. Am J Epidemiol 1989;130:904–910.PubMedGoogle Scholar
  2. 2.
    Robert CK, Ross SB. Gynecologic oncology. 2nd ed. New York: McGraw-Hill; 1993:250–255.Google Scholar
  3. 3.
    Disaia PJ, Creasman WT. Clinical Gynecologic Oncology. 4th ed. St. Louis: Mosby Year Book: 1993:387–391.Google Scholar
  4. 4.
    Ozols RF, Hamilton TC, Young RC. Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications. Prog Clin Biol Res 1986;223:173–185.PubMedGoogle Scholar
  5. 5.
    Seabright M. A rapid banding technique for human chromosomes. Lancet 1971;2:971–972.PubMedCrossRefGoogle Scholar
  6. 6.
    Miterman F (ed). ISCN 1991: Guidelines for Cancer Cytogenetics. New York: Karger; 1992:1–48.Google Scholar
  7. 7.
    Shapiro HM. Practical Flow Cytometry. 2nd ed. New York: Alan R Liss; 1988:115–140.Google Scholar
  8. 8.
    Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331–1337.PubMedCrossRefGoogle Scholar
  9. 9.
    Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979;5:957–972.PubMedCrossRefGoogle Scholar
  10. 10.
    Kjeldsen T, Clausen H, Hirohashi S, Tomoya O, Hiroyuki I, Senitiroh H. Preparation and characterization of monoclonal antibodies detected to the tumor-associated O-linked sialosyl-2 to 6 alpha-N acetyl-galactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988;48:2214–2220.PubMedGoogle Scholar
  11. 11.
    Sutton GP, Stehman FB, Einhorn HL, Roth LM, Blessing JA, Ehrich CE. Ten-year follow-up of patient receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989;7:223–229.PubMedGoogle Scholar
  12. 12.
    Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665–667.PubMedCrossRefGoogle Scholar
  13. 13.
    McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273–279.PubMedGoogle Scholar
  14. 14.
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Devidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Eng J Med 1996;334:1–6.PubMedCrossRefGoogle Scholar

Copyright information

© JSCO/CLJ 1988

Authors and Affiliations

  • Tomohiro Iida
    • 1
  • Kyoko Yonamine
    • 1
  • Hisakiyo Takeuchi
    • 1
  • Kazuhiko Hayashi
    • 1
  • Takashi Meguro
    • 2
  • Toshihito Shinagawa
    • 3
  • Akira Amemiya
    • 4
  1. 1.Department of Obstetrics and Gynecology St. Marianna University Yokohama City Seibu HospitalYokohamaJapan
  2. 2.Research Laboratory of St. Marianna University Yokohama City Seibu HospitalYokohamaJapan
  3. 3.Department of First Division of PathologySt. Marianna University School of MedicineKawasakiJapan
  4. 4.Department of Obstetrics and GynecologySt. Marianna University School of MedicineKawasakiJapan

Personalised recommendations